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Hyperleptinaemia, respiratory drive and
hypercapnic response in obese patients
A. Campo*, G. Fru¨hbeck#, J.J. Zulueta*, J. Iriarte", L.M. Seijo*, A.B. Alcaide*,
J.B. Galdiz+ and J. Salvador#
ABSTRACT: Leptin is a powerful stimulant of ventilation in rodents. In humans, resistance to
leptin has been consistently associated with obesity. Raised leptin levels have been reported in
subjects with sleep apnoea or obesity–hypoventilation syndrome. The aim of the present study
was to assess, by multivariate analysis, the possible association between respiratory centre
impairment and levels of serum leptin.
In total, 364 obese subjects (body mass index o30 kg?m-2) underwent the following tests: sleep
studies, respiratory function tests, baseline and hypercapnic response (mouth occlusion
pressure (P0.1), minute ventilation), fasting leptin levels, body composition and anthropometric
measures. Subjects with airways obstruction on spirometry were excluded.
Out of the 346 subjects undergoing testing, 245 were included in the current analysis. Lung
volumes, age, log leptin levels, end-tidal carbon dioxide tension, percentage body fat and minimal
nocturnal saturation were predictors for baseline P0.1. The hypercapnic response test was
performed by 186 subjects; log leptin levels were predictors for hypercapnic response in males,
but not in females.
Hyperleptinaemia is associated with a reduction in respiratory drive and hypercapnic response,
irrespective of the amount of body fat. These data suggest the extension of leptin resistance to the
respiratory centre.
KEYWORDS: Control of breathing, hypoventilation, leptin, obesity, respiratory centre, respiratory
function tests
O
bese subjects have respiratory impair-
ment [1] due to the increment of total
body fat, which produces diminished
compliance and increased resistance and work of
breathing. In addition, a significant proportion
suffer from obstructive sleep apnoea. A small
subgroup, most of whom have sleep apnoea
syndrome, have diurnal hypoventilation with
hypoxaemia and hypercapnia [2]. Standard pul-
monary function tests show a mild decrease in
forced vital capacity (FVC) and forced expiratory
volume in one second (FEV1), and a more evident
reduction in expiratory reserve volume (ERV).
Most of these subjects have an increased respira-
tory drive [3] and a diminished hypercapnic
response. The latter is especially true in subjects
with the obesity–hypoventilation syndrome [3, 4,].
These alterations are explained mainly by mechan-
ical factors, as the extra fat load provokes a higher
work of breathing and obstruction of the upper
airways during sleep.
Some authors have, however, proposed the
involvement of several adipose-derived factors
[5, 6]. In this context, leptin has emerged as a
relevant adipokine playing a role as a stimulant
of ventilation [5], with levels being raised in
subjects with sleep apnoea syndrome or obesity–
hypoventilation syndrome [6]. The reason for this
elevation is attributed either to stimulation by
hypoxia or to leptin insensitivity in obese
subjects. In general, subjects with hypoventilation
seem to exhibit higher levels of leptin for a given
amount of body fat.
The aim of the present study was to assess the
relationship between hyperleptinaemia and
respiratory centre parameters after adjusting for
respiratory impairment and the severity of
obesity (sleep apnoea, nocturnal desaturation,
restrictive pattern, percentage of body fat and fat
distribution, age and sex), taking into account
menopausal status in females. Serum leptin levels
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correlate mainly with body fat percentage and logarithmic
transformation improves linear correlation. Thus, log serum
leptin was chosen as an independent variable.
METHODS
Subjects
Obese adult subjects (o17 yrs old and body mass index (BMI)
o30 kg?m-2) referred for obesity treatment were included in
the current analysis. Those with a diagnosis of restrictive
pulmonary disease, neuromuscular disease or a previous
pulmonary resection were excluded. Subjects with an obstruc-
tive spirometry pattern defined as an FEV1/FVC ,70% were
also excluded. The protocol of the study was approved by the
local Ethics Committee.
Body composition
Body fat percentage was assessed by air displacement
plethysmography (Bod-Pod1; Life Measurements, Concord,
CA, USA), which is a previously validated bicompartmental
method [7]. Waist and hip circumference were measured in all
patients using a standard method [8]. Waist circumference was
measured at the midpoint between the lateral lower ribs and
the iliac crest, and hip circumference was measured at the level
of the greatest extension of the hips.
Serum leptin levels
Fasting leptin levels were measured by a double antibody
radioimmunoassay technique (Linco Research Inc., St Charles,
MO, USA). Intra- and inter-assay coefficients of variation were
5.0 and 4.5%, respectively.
Polysomnographic study
Those patients not previously tested underwent a polysomno-
graphic study. Nocturnal sleep was recorded with Harmonie
5.2 (Stellate, Montreal, QC, Canada) using Lamont 32-Sleep
amplifiers (Lamont Medical, Madison, WI, USA). The record-
ings included seven electroencephalogram channels referenced
to both balanced mastoids, right and left electroculogram,
oxygen saturation, airflow thoraco-abdominal bands, body
position sensor and electrocardiogram. Apnoea was defined as
cessation of nasal or oral airflow for o10 s. Hypopnoea was
defined as a 50% decrease in the airflow channel for 10 s. The
apnoea/hypopnoea index (AHI) was calculated as the mean
number of apnoeic and hypopnoeic events per hour of sleep.
The hypnogram was visually analysed off-line following
standard criteria, while the programme automatically calcu-
lated the AHI and the frequency and severity of oxygen
desaturations.
Lung function tests
Spirometry was performed with a calibrated, dry-rolling seal
spirometer (SensorMedics 2130 System; SensorMedics Co.,
Yorba Linda, CA, USA) according to current guidelines. Static
lung volumes were measured by body plethysmography
(SensorMedics V6200 Autobox; SensorMedics Co.). The pre-
dicted values used for spirometric and thoracic gas volumes
were those of the 1993 European update [9].
Patients underwent ventilatory drive assessment, including
minute ventilation (V9E), tidal volume(VT), inspiratory time
(tI), mouth occlusion pressure at 0.1 s of inspiration (P0.1) and
end-tidal carbon dioxide tension (PET,CO2). P0.1 was measured
using the method described by WHITELAW et al. [10].
The occlusion pressure valve was automatically occluded at
random every 2–6 respiratory cycles, using software provided
by SensorMedics. The hypercapnic response was assessed by
the method described by READ [11] and the slope of P0.1/
PET,CO2 and V9E/PET,CO2 was calculated by the minimal square
regression method.
Statistical analysis
Variables are shown as mean¡SD. The effect of sex, menopausal
status and obstructive sleep apnoea syndrome (OSAS) on the
descriptive variables was initially analysed by Mann–Whitney
U-test and the Chi-squared test. Bivariate correlations were
studied using Spearman’s rho correlation.
P0.1 analysis
Multivariate analysis was performed as a stepwise linear
regression model with baseline P0.1 as the dependent variable
and age, sex, height, waist circumference, % body fat, total
lung capacity (TLC) % predicted, baseline PET,CO2, log serum
leptin level, AHI and minimal and mean nocturnal oxygen
saturation as independent variables. Male and female subjects
were analysed both together and as separate groups.
Menopausal status was included as an independent variable
in the analysis of the females. The criteria for inclusion of
variables into the stepwise linear regression were p in 0.05,
p out 0.10 and minimal tolerance threshold (1-r2) of 0.01. A
listwise exclusion for multivariate analysis was performed.
Hypercapnic response
The analysis of the hypercapnic response was performed with
the same independent variables and slope of response (P0.1/
PET,CO2) as the dependent variable. A similar regression
analysis was performed using V9E/PET,CO2 as the dependent
variable.
RESULTS
Descriptive data
In total, 364 subjects were included in the present study.
Descriptive variables and differences between sex and between
pre- and post-menopausal females are shown in table 1. The
number of subjects undergoing the different tests is shown in
table 2. Following exclusion of missing values from the
multivariate analysis, 245 subjects were included in analysis
of baseline respiratory centre assessment and 186 in the
hypercapnic response assessment.
Sleep studies were performed in 194 females and 104 males.
The AHI was between 5 and 30 ?h-1 in 29.7 and 23.3% of
females and males, respectively, and .30 ?h-1 in 15.1 and
44.7% of females and males, respectively (p,0.001).
Respiratory drive measurements were not different between
subjects with or without OSAS (AHI. or ,15 ?h-1, respec-
tively) after stratifying by sex, as shown in table 3. Subjects
with OSAS had a greater BMI, a larger waist circumference
and a higher respiratory impairment.
The relationship between the percentage of body fat and leptin
improved with logarithmic transformation; the linear correla-
tion between leptin and percentage of body fat was stronger
using log leptin (R50.629) rather than leptin (R50.565). The
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correlation of body fat and log leptin was 0.342 and 0.513 for
females and males, respectively.
Bivariate correlations
Bivariate correlations are shown in tables 4, 5 and 6 for P0.1,
hypercapnic response by P0.1 and hypercapnic response by
minute ventilation, respectively. Each table provides data for
the whole sample, males and females.
Multivariate analysis models
The multivariate analysis included the following variables:
age, obesity parameters (percentage of body fat and fat
distribution), log leptin levels, pulmonary function (TLC %
pred) and sleep study parameters (AHI, minimal and mean
nocturnal saturation). Analysis of the whole group included
sex as a variable, and the analysis of females included
menopausal status. After bivariate analysis, waist–hip ratio
and waist circumference were used as a measurement of fat
distribution in males and females, respectively.
The results of the multiple linear regression analyses are
summarised in table 7. Figure 1 shows significant adjusted
partial correlation between log leptin levels and P0.1 in males
and pre-menopausal females and log leptin levels and
hypercapnic response in males, after the multivariate analysis.
Other partial correlations between respiratory centre para-
meters and significant variables after multivariate analysis are
shown in the supplementary material.
Baseline P0.1
The variables associated with P0.1 in the whole sample were
age, percentage of body fat, log leptin levels, TLC % pred,
baseline PET,CO2 and minimal nocturnal saturation. In males,
the associated variables were percentage of body fat, log leptin
TABLE 1 Subject characteristics and comparison by sex and menopausal status
Total Comparison by sex Comparison by menopausal status in females
Females Males p-value Non-menopausal Menopausal p-value
Age yrs 43.1¡12.9 43.7¡13.1 42.1¡12.4 0.256 35.53¡9.71 57.18¡6.25 ,0.001
Smoking 0.044 0.043
Current 94 (26) 59 (25.8) 35 (26.5) 43 (33.1) 12 (16.7)
Former 103 (28.5) 56 (24.5) 47 (35.6) 29 (22.3) 20 (27.8)
Never 164 (45.4) 114 (49.8) 50 (37.9) 58 (44.6) 40 (55.6)
BMI kg?m-2 43.0¡6.86 43.0¡7.0 42.91¡6.6 0.890 43.33¡6.83 42.43¡7.52 0.276
Waist–hip ratio 0.94¡0.09 0.904¡0.08 1.002¡0.08 ,0.001 0.88¡0.07 0.94¡0.07 ,0.001
Waist cm 122¡14 117¡13 129¡13 ,0.001 116.8¡13 119.72¡12 0.093
Body fat % 48.9¡7.2 52.2¡4.9 42.9¡6.8 ,0.001 52.18¡4.93 52.64¡4.29 0.638
Leptin mg?L-1 54.5¡30.2 65.4¡29.3 36.0¡21.4 ,0.001 64.91¡30.13 64.64¡28.96 0.993
Log leptin mg?L-1 1.666¡0.259 1.769¡0.212 1.491¡0.238 ,0.001 1.76¡0.22 1.76¡0.21 0.993
Log leptin/fat % 3.487¡0.490 3.408¡0.434 3.506¡0.553 0.159 3.39¡0.44 3.39¡0.39 0.926
TLC % pred 88.93¡11.66 92.19¡10.56 83.32¡11.39 ,0.001 92.50¡10.71 91.56¡10.54 0.578
Baseline P0.1 cmH2O 4.51¡1.87 4.385¡1.833 4.738¡1.921 0.084 4.49¡1.68 3.82¡1.35 ,0.001
Baseline PET,CO2 mmHg 33.32¡5.75 32.97¡5.743 33.93¡5.72 0.126 32.51¡5.34 34.27¡5.77 0.025
P0.1/(VT/tI) cmH2O?L
-1?s-1 7.735¡3.020 7.850¡2.885 7.536¡3.242 0.086 8.00¡2.68 7.05¡2.53 0.007
P0.1/PET,CO2 cmH2O/mmHg 1.01¡0.90 0.87¡0.84 1.27¡0.94 ,0.001 0.90¡0.88 0.82¡0.75 0.776
V9E/PET,CO2 L?min
-1/mmHg 2.61¡1.87 2.07¡1.27 3.60¡2.34 ,0.001 2.15¡1.28 1.92¡1.29 0.251
AHI h-1 22.05¡25.35 15.53¡18.21 34.21¡31.64 ,0.001 13.79¡18.54 20.05¡18.76 0.002
Minimal Sp,O2 % 80.55¡11.17 82.13¡10.64 77.63¡11.56 0.001 84.4¡10.31 78.63¡10.78 ,0.001
Mean Sp,O2 % 94.50¡2.83 94.83¡2.61 93.92¡3.12 0.016 95.46¡2.45 93.69¡2.81 ,0.001
Variables are shown as mean¡SD and categorical variables as absolute count n (%). BMI: body mass index; TLC: total lung capacity; % pred: % predicted; P0.1: mouth
occlusion pressure; PET,CO2: end-tidal carbon dioxide tension; VT: tidal volume; tI: time taken for inspiration; V9E: minute ventilation; AHI: apnoea/hypopnoea index; Sp,O2:
arterial oxygen saturation. 1 mmHg50.133 kPa.
TABLE 2 Number of subjects who underwent each test
Females Males Total
Spirometry 231 (100) 133 (100) 364 (100)
Baseline P0.1/ respiratory
pattern
229 (99.1) 132 (99.25) 361 (99.2)
Hypercapnic response 159 (68.8) 86 (64.7) 245 (67.3)
Polysomnographic study 194 (84) 104 (78.2) 298 (81.87)
AHI 192 (83.1) 103 (77.4) 295 (81.0)
Minimal Sp,O2 % 195 (84.4) 106 (79.7) 301 (82.69)
Mean Sp,O2 % 174 (75.3) 96 (72.2) 270 (74.2)
Body composition 220 (95.2) 125 (94.0) 345 (94.8)
Leptin 224 (97) 131 (98.5) 355 (97.5)
Waist 223 (96.5) 131 (98.5) 354 (97.3)
Data are presented as n (%). P0.1: mouth occlusion pressure; AHI: apnoea/
hypopnoea index; Sp,O2: arterial oxygen saturation.
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TABLE 3 Differences between subjects with and without obstructive sleep apnoea syndrome (OSAS) stratified by sex
Male Female
Without OSAS With OSAS p-value Without OSAS With OSAS p-value
Subjects n 42 61 125 67
Age yrs 35.8¡11.9 44.4¡10.9 ,0.001 41.2¡12.8 47.7¡12.3 ,0.001
Height cm 1.76¡0.6 1.75¡0.1 0.382 1.61¡0.1 1.61¡0.1 0.490
BMI 40.5¡6.9 44.8¡6.2 ,0.001 42.6¡5.6 44.3¡7.7 0.227
Waist 124.7¡13.5 132.6¡12.6 0.001 115.8¡11.9 122.45¡13.7 0.002
Waist–hip ratio 0.99¡0.07 1.01¡0.07 0.234 0.89¡0.07 0.93¡0.07 0.001
Body fat % 40.9¡6.9 44.4¡6.4 0.017 52.2¡4.6 52.5¡5.0 0.500
AHI n?h-1 5.96¡3.9 53.7¡27.4 ,0.001 5.32¡4.0 34.6¡19.1 ,0.001
Sp,min 86.3¡4.6 71.8¡11.4 ,0.001 85.1¡8.2 76.7¡12.6 ,0.001
Sp,med 95.5¡1.8 92.8¡3.4 ,0.001 95.4¡1.9 93.6¡3.38 ,0.001
Sp,O2 % time ,90% 1.07¡1.93 18.58¡21.1 ,0.001 3.46¡10.6 11.42¡19.3 ,0.001
TLC % 84.6¡10.1 82.3¡12.2 0.292 92.1¡10.4 92.7¡10.7 0.807
FVC % 98.2¡13.2 92.0¡14.5 0.022 104.7¡12.1 103.2¡17.0 0.398
ERV % 54.4¡21.6 44.2¡24.5 0.010 61.4¡27.2 46.5¡21.2 ,0.001
PET,CO2 32.5¡5.4 34.8¡5.3 0.047 32.4¡5.7 34.3¡5.8 0.016
Baseline P0.1 4.57¡1.8 4.77¡1.9 0.582 4.52¡2.1 4.25¡1.5 0.853
Delta P0.1/PET,CO2 1.15¡0.73 1.37¡0.99 0.396 0.95¡0.90 0.73¡0.78 0.174
Delta V9E/PET,CO2 3.33¡1.96 4.12¡2.4 0.152 2.18¡1.3 1.85¡1.09 0.272
Log leptin 1.47¡0.25 1.51¡0.23 0.295 1.78¡0.21 1.77¡0.22 0.422
Log leptin/% body fat 3.64¡0.48 3.43¡0.61 0.025 3.43¡0.42 3.40¡0.48 0.357
Data are presented as mean¡SD, unless otherwise indicated. BMI: body mass index; AHI: apnoea/hypopnoea index; Sp,min: minimal nocturnal arterial oxygen saturation
(Sp,O2); Sp,med: mean nocturnal Sp,O2; TLC: total lung capacity; FVC; forced vital capacity; ERV: expiratory reserve volume; PET,CO2: end-tidal carbon dioxide tension; P0.1:
mouth occlusion pressure; V9E: minute ventilation.
TABLE 4 Spearman’s rho bivariate correlations for baseline mouth occlusion pressure (P0.1)
Variable Whole sample Males Females
Rho p-value Rho p-value Pre-menopausal Post-menopausal
Rho p-value Rho p-value
Height 0.092 0.080 0.071 0.421 -0.060 0.498 -0.012 0.923
Age -0.154 0.003 -0.080 0.360 -0.092 0.296 -0.045 0.708
% body fat 0.088 0.104 0.241 0.007 0.227 0.010 -0.031 0.807
Leptin -0.048 0.371 0.010 0.908 -0.024 0.787 -0.035 0.775
Log leptin -0.048 0.371 0.010 0.908 -0.024 0.787 -0.035 0.775
Leptin# -0.151 0.005 -0.143 0.117 -0.126 0.164 -0.081 0.530
Log leptin# -0.146 0.008 -0.153 0.093 -0.105 0.249 -0.063 0.626
Log leptin/% body fat -0.176 0.001 -0.259 0.004 -0.161 0.075 0.014 0.912
Waist 0.147 0.006 0.105 0.233 0.125 0.161 0.058 0.636
Waist–hip ratio -0.053 0.319 -0.256 0.003 0.015 0.864 0.104 0.397
TLC % pred -0.125 0.018 -0.220 0.011 -0.024 0.783 -0.033 0.783
PET,CO2 -0.261 ,0.001 -0.251 0.004 -0.276 0.001 -0.147 0.222
AHI 0.034 0.567 -0.031 0.754 0.123 0.200 0.040 0.774
Minimal Sp,O2 -0.076 0.192 -0.017 0.863 -0.132 0.160 -0.097 0.480
Mean Sp,O2 -0.065 0.289 -0.084 0.414 -0.170 0.084 -0.063 0.659
Sex 0.092 0.080
TLC: total lung capacity; % pred: % predicted; PET,CO2: end-tidal carbon dioxide tension; AHI: apnoea/hypopnoea index; Sp,O2: arterial oxygen saturation.
#: bivariate
correlations adjusted by % body fat.
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levels, TLC % pred, baseline PET,CO2, minimal nocturnal
saturation and waist–hip ratio. In this group, log leptin levels
accounted for a change in r2 of 0.029, with a p-value for the
change in F of 0.050. The analysis in females showed a
significant association with log leptin levels in pre-menopausal
but not in post-menopausal females, which accounted for a
change in r2 of 0.05 (p50.017). The other explanatory variables
in this group were age, percentage of body fat and PET,CO2.
TABLE 5 Bivariate correlations with hypercapnic response (mouth occlusion pressure/end-tidal carbon dioxide tension (PET,CO2))
Variable Whole sample Males Females
Rho p-value Rho p-value Pre-menopausal Post-menopausal
Rho p-value Rho p-value
Height 0.252 ,0.001 0.077 0.480 0.165 0.110 0.173 0.234
Age -0.120 0.062 -0.053 0.626 -0.111 0.283 -0.185 0.203
% body fat -0.229 ,0.001 0.085 0.457 -0.077 0.468 -0.232 0.125
Leptin -0.151 0.019 0.010 0.931 -0.002 0.988 0.036 0.809
Log leptin -0.151 0.019 -0.010 0.931 -0.002 0.988 0.036 0.809
Leptin# -0.072 0.281 -0.148 0.200 -0.051 0.633 0.155 0.315
Log leptin# -0.094 0.156 -0.256 0.025 -0.030 0.780 0.163 0.291
Log leptin/% body fat 0.104 0.121 -0.123 0.288 0.072 0.503 0.359 0.017
Waist -0.018 0.779 -0.029 0.796 -0.148 0.155 -0.090 0.541
Waist–hip ratio 0.084 0.193 -0.158 0.152 -0.102 0.328 0.101 0.493
TLC% pred -0.059 0.360 -0.065 0.550 0.045 0.668 0.122 0.402
PET,CO2 0.034 0.600 -0.114 0.295 0.024 0.816 0.026 0.862
AHI 0.056 0.428 0.052 0.671 -0.052 0.642 -0.102 0.536
Sp,min 0.112 0.108 -0.019 0.879 0.226 0.038 0.071 0.666
Sp,med 0.080 0.258 -0.141 0.260 0.222 0.042 0.167 0.309
Sex 0.256 ,0.001
TLC: total lung capacity; % pred: % predicted; AHI: apnoea/hypopnoea index; Sp,min: minimal nocturnal arterial oxygen saturation (Sp,O2); Sp,med: mean nocturnal Sp,O2.
#: bivariate correlations adjusted by % body fat.
TABLE 6 Bivariate correlations for hypercapnic response (minute ventilation/end-tidal carbon dioxide tension (PET,CO2))
Variable Whole sample Males Females
Rho p-value Rho p-value Pre-menopausal Post-menopausal
Rho p-value Rho p-value
Height 0.393 ,0.001 0.309 0.004 0.242 0.018 0.009 0.950
Age -0.134 0.036 0.003 0.978 -0.190 0.066 -0.049 0.737
% body fat -0.289 ,0.001 0.038 0.739 -0.122 0.247 -0.118 0.439
Leptin -0.191 0.003 0.026 0.813 0.025 0.810 0.002 0.987
Log leptin -0.191 0.003 0.026 0.813 0.025 0.810 0.002 0.987
Leptin# -0.068 0.308 -0.083 0.476 0.070 0.512 0.022 0.887
Log leptin# -0.098 0.141 -0.142 0.217 0.077 0.466 0.031 0.844
Log leptin/% body fat 0.104 0.119 -0.085 0.464 0.137 0.200 0.184 0.231
Waist 0.042 0.513 0.162 0.142 -0.207 0.046 -0.175 0.234
Waist–hip ratio 0.168 0.009 0.041 0.709 -0.089 0.394 0.063 0.669
TLC % pred -0.019 0.773 -0.002 0.984 0.113 0.279 0.345 0.015
PET,CO2 0.000 0.996 -0.109 0.319 0.043 0.681 -0.247 0.087
AHI 0.122 0.082 0.072 0.562 0.013 0.909 -0.003 0.984
Sp,min 0.075 0.284 -0.053 0.669 0.281 0.010 0.238 0.145
Sp,med 0.034 0.634 -0.159 0.202 0.250 0.022 0.222 0.175
Sex 0.364 ,0.001
TLC: total lung capacity; % pred: % predicted; AHI: apnoea/hypopnoea index; Sp,min: minimal nocturnal arterial oxygen saturation (Sp,O2); Sp,med: mean nocturnal Sp,O2.
#: bivariate correlations adjusted by % body fat.
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Hypercapnic response
The multivariate analysis for hypercapnic response showed
that the explained variability of the slope of P0.1/PET,CO2 was
5.6% (p50.002), with height and leptin levels as the only
explanatory variables. The separate analyses showed that log
leptin level was the only explanatory variable in males
(r250.051; p50.027), but was not an explanatory variable in
females.
The regression analysis for V9E/PET,CO2 showed an explained
variability of 26.1% (p,0.001), with height and log leptin levels
as independent variables. The separate analyses showed that
height was the only explanatory variable in males. In pre-
menopausal females, height and waist were explanatory
variables; in post-menopausal females, TLC % pred was the
only independent variable.
DISCUSSION
The present study demonstrates that in obese patients, higher
concentrations of serum leptin are associated with a reduced
respiratory drive and a reduced hypercapnic response. As
leptin is a stimulant of ventilation, these results suggest an
extension of leptin resistance to the respiratory centre. Clinical
studies of obesity–hypoventilation syndrome have suggested
an association between respiratory drive and leptin but this
has not previously been demonstrated.
Leptin, the product of the Ob gene, is a protein secreted by
adipocytes that regulates body weight [12–14] by increasing
satiety and reducing food intake. Serum leptin levels correlate
with body fat percentage [15]. It has been shown that, in mice,
leptin deficiency induced by an Ob gene mutation is associated
with morbid obesity, hyperphagia, insulin resistance and
hypoventilation. Seminal studies in animals describe the
characteristic hypoventilation of mice associated with Ob
mutation and the subsequent improvement with exogenous
leptin administration, even before the consequent reduction in
body weight [5]. Prolonged treatment (6 weeks) with leptin in
leptin-deficient mice modifies the animal’s ventilatory pattern,
increases lung compliance and restores the abnormal adapta-
tion of the diaphragm [16]. While most obese subjects have
markedly increased levels of plasma leptin, only a few cases of
human genetic abnormalities of leptin have been reported.
Obesity has been postulated to be a state of leptin resistance.
Two distinct mechanisms of resistance have been proposed in
human obesity: an impaired transport of leptin across the
blood–brain barrier [17, 18] and altered signalling pathways or
receptors. Leptin resistance can also be induced by feeding
animals a high-fat diet [19].
The possible interaction between leptin and ventilatory
parameters in humans is not as clear as that seen in animal
models. Most of the studies in this regard have investigated the
relationship between leptin levels, sleep apnoea syndrome and
obesity–hypoventilation syndrome. However, there are no
studies assessing the relationship between the respiratory
centre and leptin in humans.
Compared with BMI-matched controls, higher plasma levels of
leptin are described in hypercapnic obese subjects and those
with OSAS [20, 21]. Furthermore, treatment of the latter with
continuous positive airway pressure reduces plasma leptin
levels [22–26]. Possible explanations for the reduction in leptin
levels after treatment include a change in fat distribution [25],
an improvement in sympathetic function [27] or an improve-
ment in leptin sensitivity. However, the existence of an
independent association between leptin and OSAS is con-
troversial. Some studies have failed in their attempts to
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FIGURE 1. Partial correlations between log leptin levels and respiratory control
parameters that were significant in the multivariate analysis. a) Partial correlation
between log leptin levels and baseline mouth occlusion pressure (P0.1) in males
after adjusting multivariate analysis. r250.0795. b) Correlation between log leptin
levels and delta P0.1/end-tidal carbon dioxide tension (PET,CO2) in males. r
250.0406.
c) Partial correlation between log leptin levels and baseline P0.1 in pre-menopausal
females after adjusting multivariate analysis. r250.0253.
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demonstrate the existence of this relationship, independent of
adiposity [26, 28].
Another hypothesis is that hypoxaemia causes leptin secretion;
this has been shown in experimental studies [29]. In this hypo-
thesis, leptin resistance and hyperleptinaemia might not cause
hypoventilation but might be caused by it. TATSUMI et al. [30]
studied 96 male nonobese patients with OSAS and 52 male
patients without OSAS matched for BMI, and found that the
average arterial oxygen saturation (Sa,O2) and lowest Sa,O2 were
explanatory variables for serum leptin values, but AHI, BMI,
visceral fat or subcutaneous fat were not. These results suggest
that the elevation of leptin levels was a consequence of hypoxia
and not of fat accumulation.
The present study analysed a larger size sample (245 subjects)
than in previous studies, and in addition to body composition,
also took into account fat distribution, nocturnal saturation,
AHI, pulmonary function and sex. Leptin levels were an
independent factor of respiratory drive, independent of
apnoea events, nocturnal saturation, restrictive impairment
or fat distribution. There are no previous studies in humans
that analyse correlate respiratory drive measurements with
leptin, although the relationship between hypercapnia and
circulating leptin levels has been reported. However, as the
present study is a cross-sectional study, the results cannot
imply causality. These results are significant in the whole
sample and in males, but the association in females could not
be demonstrated. The association is weak, and log leptin levels
account only for a 2.9 and 6.3% of the variance of baseline P0.1
and delta P0.1/PET,CO2 in males, so the size of the sample and
the differences in the behaviour of leptin in females might
explain the lack of significance in females.
PHIPPS et al. [6] found higher serum leptin levels in subjects
with obesity–hypoventilation syndrome than in subjects with
the same amount of body fat but without hypoventilation; the
severity of OSAS had no effect. SHIMURA et al. [31] studied 185
male patients with OSAS (106 eucapnic and 79 hypercapnic) in
which visceral and subcutaneous fat distribution was assessed
by computed tomography. They found that leptin, and not fat
distribution, was the only predictor of hypercapnia. No
association was found between circulating leptin levels and
AHI, nocturnal mean and nadir oxygen saturation, percentage
of FVC, FEV1/FVC or fat content. They suggest that
hypoventilation in OSAS is partly due to depressed sensitivity
to leptin in the CNS.
One limitation of the present study is that arterial blood gas
analysis was not performed, so it is impossible to be certain as
to how many of the present study’s subjects had established
hypoventilation–obesity syndrome.
In the present study, respiratory drive measured as baseline
P0.1 was increased with respect to other studies [32, 33],
although a control group assessment was not performed. There
was a significant and independent correlation between the
presence of a restrictive impairment and the increment in
respiratory drive, as has been seen in obese subjects. This
suggests a stimulation of the respiratory centre by the
increased work of breathing. Respiratory drive also correlated
positively with the severity of obesity defined as percentage
body fat, and inversely with baseline PET,CO2, age and minimal
nocturnal saturation. The nadir Sp,O2 was an independent
variable for baseline P0.1 in males and post-menopausal
females. The respiratory centre parameters were not different
between subjects with and without OSAS.
Bivariate analysis did not demonstrate significant correlations
between AHI and ventilatory control parameters, although
there were significant correlations with nocturnal saturation
indices. However, the effect of respiratory disorders during
sleep was also assessed by including AHI and minimal and
mean nocturnal saturation in the multivariate analysis.
No association was found between the AHI or saturation
parameters with hypercapnic response. Studies have found
that the hypercapnic response is increased in obese females
irrespective of the presence of sleep apnoea syndrome,
whereas the hypoxic response is significantly increased in
obese females with OSAS compared with obese females
without OSAS [34].
The hypercapnic response in males, measured by the increase
in minute ventilation, had a strong correlation with height, as
height correlates with absolute TLC and baseline minute
ventilation. In females this response correlated with height but
also with the presence of a restrictive pattern and waist
circumference, probably reflecting mechanical limitations for
ventilation.
Differences in variables between sexes were analysed. Several
obesity and respiratory variables, but not BMI, were signifi-
cantly different between males and females. Females had a
different fat distribution, higher circulating leptin levels and a
greater percentage of body fat, but fewer alterations in lung
volumes and fewer and milder respiratory disorders during
sleep. Sexual dimorphism in leptin levels has been repeatedly
reported [35]. This finding may be attributed to the different
distribution of fat in both sexes, as visceral fat produces less
leptin and is found in higher proportion in males. However, no
effect of female sex or menopausal status was found on the
respiratory centre measurements.
In conclusion, a lower respiratory drive in obese subjects is
associated with higher serum leptin levels, adjusted by
ventilatory parameters, age, severity of obesity, apnoea–
hypopnoea index and nocturnal saturation. In males higher
leptin levels are also associated with a lower hypercapnic
response. These results suggest an extension of leptin
resistance to the respiratory centre in obese subjects.
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